Feasibility of Proton Beam Therapy as a Rescue Therapy in Heavily Pre-Treated Retinoblastoma Eyes.
EBRT
eye preserving therapy
in-field malignancies
subsequent primary malignancies
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
28
02
2021
revised:
09
04
2021
accepted:
11
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Despite the increased risk of subsequent primary tumors (SPTs) external beam radiation (EBRT) may be the only therapeutic option to preserve a retinoblastoma eye. Due to their physical properties, proton beam therapy (PBT) offers the possibility to use the effectiveness of EBRT in tumor treatment and to decisively reduce the treatment-related morbidity. We report our experiences of PBT as rescue therapy in a retrospectively studied cohort of 15 advanced retinoblastoma eyes as final option for eye-preserving therapy. The average age at the initiation of PBT was 35 (14-97) months, mean follow-up was 22 (2-46) months. Prior to PBT, all eyes were treated with systemic chemotherapy and a mean number of 7.1 additional treatments. Indication for PBT was non-feasibility of intra-arterial chemotherapy (IAC) in 10 eyes, tumor recurrence after IAC in another 3 eyes and diffuse infiltrating retinoblastoma in 2 eyes. Six eyes (40%) were enucleated after a mean time interval of 4.8 (1-8) months. Cataract formation was the most common complication affecting 44.4% of the preserved eyes, yet 77.8% achieved a visual acuity of >20/200. Two of the 15 children treated developed metastatic disease during follow-up, resulting in a 13.3% metastasis rate. PBT is a useful treatment modality as a rescue therapy in retinoblastoma eyes with an eye-preserving rate of 60%. As patients are at lifetime risk of SPTs consistent monitoring is mandatory.
Identifiants
pubmed: 33924716
pii: cancers13081862
doi: 10.3390/cancers13081862
pmc: PMC8069965
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer. 2014 Jan 1;120(1):126-33
pubmed: 24122173
Tex Med. 2005 Jul;101(7):10
pubmed: 16152902
Klin Padiatr. 2010 May;222(3):127-33
pubmed: 20514614
Adv Radiat Oncol. 2017 Jan-Mar;2(1):44-52
pubmed: 28607957
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):583-93
pubmed: 15667981
Ophthalmology. 2014 Sep;121(9):1810-7
pubmed: 24819859
Clin Exp Ophthalmol. 2008 Jan-Feb;36(1):78-89
pubmed: 18290958
Annu Rev Med. 2014;65:171-84
pubmed: 24422571
Pediatr Blood Cancer. 2017 Jan;64(1):71-80
pubmed: 27567086
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e151-5
pubmed: 23273995
J Natl Cancer Inst. 2009 Apr 15;101(8):581-91
pubmed: 19351917
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
Front Radiat Ther Oncol. 1997;30:65-80
pubmed: 9205886
Yonsei Med J. 2015 Nov;56(6):1478-91
pubmed: 26446627
Curr Opin Ophthalmol. 2016 Sep;27(5):443-8
pubmed: 27213925
J Pediatr Hematol Oncol. 2018 Nov;40(8):569-573
pubmed: 29683953
Cancer Control. 2016 Apr;23(2):99-109
pubmed: 27218786
Acta Ophthalmol. 2018 Sep;96(6):631-640
pubmed: 29537141
Korean J Ophthalmol. 2017 Feb;31(1):52-57
pubmed: 28243024
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
Korean J Ophthalmol. 2011 Dec;25(6):387-93
pubmed: 22131775
Prog Retin Eye Res. 2019 Nov;73:100764
pubmed: 31173880
J Clin Oncol. 2000 Jan;18(1):12-7
pubmed: 10623688
Br J Radiol. 2020 Mar;93(1107):20190601
pubmed: 31529979
Br J Ophthalmol. 2009 Jul;93(7):891-4
pubmed: 19329423
J Clin Oncol. 2005 Apr 1;23(10):2272-9
pubmed: 15800318
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9
pubmed: 19066271
Ophthalmology. 2005 Sep;112(9):1620-4
pubmed: 16024083
J Clin Oncol. 2016 Sep 10;34(26):3183-8
pubmed: 27382102
Br J Ophthalmol. 2014 Mar;98(3):292-7
pubmed: 24187047
Br J Ophthalmol. 2014 Oct;98(10):1355-9
pubmed: 24795337
JAMA Ophthalmol. 2015 Nov;133(11):1341-7
pubmed: 26378747
Phys Med. 2017 Nov;43:15-24
pubmed: 29195558
J Neurointerv Surg. 2019 Dec;11(12):1266-1272
pubmed: 31103993
Am J Ophthalmol. 2002 May;133(5):657-64
pubmed: 11992863
Curr Opin Ophthalmol. 2012 May;23(3):202-9
pubmed: 22450222
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):863-9
pubmed: 25227498